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Efﬁcient transcytosis across the blood-brain-barrier (BBB) is an important strategy for accessing drug
targets within the central nervous system (CNS). Despite extensive research the number of studies
reporting successful delivery of macromolecules or macromolecular complexes to the CNS has remained
very low. In order to expand current research it is important to know which receptors are selective and
abundant on the BBB so that novel CNS-targeting antibodies or other ligands could be developed, tar-
geting those receptors for transcytosis. To do that, we have set up a proteomics- and transcriptomics-
based workﬂow within the COMPACT project (Collaboration on the Optimization of Macromolecular
Pharmaceutical Access to Cellular Targets) of the Innovative Medicines Initiative (IMI) of the EU. Here we
summarise our overall strategy in endothelial transcytosis research, describe in detail the related chal-
lenges, and discuss future perspectives of these studies.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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remained a great challenge in biomedical research and clinical
sciences despite rigorous efforts for more than two decades. This is
because the blood-brain-barrier (BBB) represents one of the most
tightly regulated and complex biological barriers in mammals with
a function to protect the brain from damage of unwanted blood-
borne molecules. This is essential for maintaining correct neuro-
logical functions. However, in case of neurological disease, the
delivery of therapeutic bioactive macromolecular compounds toartment of Physiology, Anat-
s Road, OX1 3QX Oxford, UK.
er).
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g/10.1016/j.neuropharm.2016affected areas of the central nervous system (CNS) is highly desired
but notoriously difﬁcult to achieve, especially when the general
protective barrier function of the BBB is to be maintained. This
explains the failure of clinical trials of numerous biologicals tar-
geted to the CNS (Pardridge, 2015a).
To overcome this problem, many attempts have been made to
ﬁnd speciﬁc targeting ligands, endogenous proteins or antibodies
against certain receptors (e.g. transferrin receptor (TFRC) and in-
sulin receptor (INSR)) that could be used to induce receptor-
mediated transcytosis of therapeutic biologicals across the BBB.
For example, TFRC antibody chimeras have been successfully used
in animalmodels of Parkinson's disease, stroke, Alzheimer's disease
and lysosomal storage disease for enhancing brain accumulation of
therapeutic proteins (Watts and Dennis, 2013; Pardridge, 2015b;under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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antibody and therapeutic protein fusions have shown great po-
tential in non-human primates for treating mucopolysaccharidosis
type I (MPS-I) and Alzheimer's disease, and also in brain delivery of
GDNF, TNFR, erythropoietin and paraoxonase-1 (Lajoie and Shusta,
2015). To deliver drugs across the BBB independently of speciﬁc
targeting ligands, the barrier can be temporarily opened in some
conditions by using microbubbles and focussed ultrasound. Initial
safety and efﬁcacy data, incl. the treatment of a brain tumour pa-
tient, are promising and indicate that concerns about risks related
to the loss of BBB integrity could be managed (Piper et al., 2016;
Lipsman et al., 2014; Sunnybrook). However, the advantages and
disadvantages compared to the receptor-mediated BBB transcytosis
need further thorough evaluation.
Receptor-mediated transcytosis across the BBB is an attractive
strategy for reaching targets within the CNS for various reasons. For
example, it could enable the transport of macromolecules or
macromolecular complexes that would be unfeasible in carrier-
mediated transport systems (i.e. channels and carriers)
(Pardridge, 2012). Furthermore, alternative CNS entry routes such
as via injection into the cerebrospinal ﬂuid (CSF) are generally
regarded as unfavourable because it requires hospitalization of the
patient, because of the risk of infection, and due to the rapid drug
export from the CSF back to blood circulation (Pardridge, 2012).
The architecture of brainmicrocapillary network is favourable to
receptor-mediated transcytosis too. The distance between adjacent
vessels in the brain is in the range of 40e60 mm (Pardridge, 2015a;
Nicholson, 2001; Duvernoy et al., 1983). Taking account the size of
neurons, the cell body of a neuron is no further than 10e20 mm
from the closest capillary on average (Wong et al., 2013; Schlageter
et al., 1999). This means that the diffusion distance of the traversed
macromolecular compounds is short enough to diffuse to neurons
in the time scale from seconds to tens of minutes (but could be
longer in a crowded environment), depending on the molecular
weight of the compound (Atkins and de Paula, 2006). However,
achieving transcytosis across the BBB requires thorough under-
standing of brain microendothelial cells surface proteins.
One of the crucial questions is how to ﬁnd receptors which are
(a) selective to the brain microvasculature, (b) expressed at sufﬁ-
ciently high levels and (c) could be used for transcytosis. Further-
more, once these receptors have been identiﬁed, it is an additional
challenge to ﬁnd ligands/antibodies capable of taking advantage of
transcytosis of these receptors for drug delivery. These questions
address the issue how to reach the interstitial space of the brain
tissue. However another layer of complexity is added when the
drug target is in the intracellular environment of neurons, requiring
cell uptake and delivery to required cell compartment.
Within the COMPACT project (Collaboration on the Optimiza-
tion of Macromolecular Pharmaceutical Access to Cellular Targets)
of the Innovative Medicines Initiative (IMI) of the EU (http://www.
imi.europa.eu/content/compact), we have developed and set up a
workﬂow to identify brain microvascular cell surface speciﬁc re-
ceptors (Fig. 1) with an aim to use them for drug delivery across the
BBB. The workﬂow is based on analysing the cell surface proteome
and whole cell transcriptome.
The need to thoroughly characterise individual molecular con-
stituents of the BBB for ﬁnding novel BBB-speciﬁc receptors for
drug delivery has been recognized by many. Recent advances in
proteomics and transcriptomics have enabled detailed compari-
sons of human and small animal model BBB properties, which in
turn helps to select human relevant brain-speciﬁc receptors for
drug delivery with a possibility to study them in animal models
(Ohtsuki et al., 2014; Enerson and Drewes, 2006; Zhang et al., 2014).
Even though the gene expression proﬁle of BBB endothelial cells is
heterogeneous (Macdonald et al., 2010), by analysing brainPlease cite this article in press as: M€ager, I., et al., Targeting bl
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leads for brain-speciﬁc transporters and other proteins with drug
delivery potential (Daneman et al., 2010). Recent data indicate that
by combining transcriptomic analysis and proteomic proﬁling of
brain endothelial cells in mice, new target receptors can be
discovered that mediate therapeutic antibody transcytosis to brain
more efﬁciently than TFRC and INSR binding antibodies in mice
(Zuchero et al., 2016). For exploiting unknown receptors for BBB
transcytosis, assays such as phage display panning has been used
(Jones et al., 2014; Muruganandam et al., 2002; Smith et al., 2012).
In order to identify brain microvasculature selective receptors it
is essential to proﬁle microvascular cells also from other tissues for
comparison. Because many nanoparticle drug delivery formula-
tions accumulate in liver and lung, the ﬁrst choice is to include
microvascular cells from these organs to the comparison (Fig. 1).
However, it must kept in mind that drug formulations can accu-
mulate in those vessels not only in receptor-speciﬁc manner;
nonspeciﬁc physical capture can be important too. There are two
principal strategies for proﬁling the cells, comparing either (a) cell
transcriptomes, e.g. by next generation sequencing (NGS) (Fig. 1, A),
or (b) cell surface proteomes by LC-MS/MS (Fig.1, B). Both strategies
have clear advantages and disadvantages. NGS is sensitive enough
for allowing the analysis of RNA from freshly isolated primary
microendothelial cells without requiring prior cell culture, a pro-
cess that potentially impacts the gene/protein expression proﬁle of
isolated primary cells. Freshly isolated mRNA samples are even
available from commercial vendors. However, NGS based mRNA
expression proﬁles may not fully match in a qualitative and quan-
titative manner the expressed cell proteome. Furthermore, it is also
unclear whether membrane proteins, even when effectively
translated, are sorted to the plasmamembrane for being exposed to
potential targeting ligands or targeting antibodies.
These drawbacks can partially be addressed by performing a cell
surface proteomics experiment. Cell surface proteins can be
labelled, for example with biotin by using appropriate kits, and
pulled down using magnetic beads. By analysing protein compo-
sition of these samples it is possible to claim with high conﬁdence
which receptors are presented on cell surface and therefore
accessible to targeting ligands and antibodies. However, in order to
obtain enough material for proteomics it may be necessary to
subculture the isolated primary microendothelial cells ﬁrst, before
extracting the proteins. It is well documented that this process can
considerably change the gene/protein expression proﬁle of cells, for
example the loss of certain tight junction proteins (Cecchelli et al.,
2007; Abbott et al., 2006; Nakagawa et al., 2009). Furthermore,
proteomic proﬁling does not aid in the discovery of non-protein
receptors such as gangliosides and/or glycans. All these aspects
must be taken into account when interpreting the cell surface
proteomics data.
In order to minimise risks associated with the both strategy it is
important to conduct mRNA sequencing and proteomics experi-
ments in parallel. Understanding similarities and differences of
identiﬁed receptors is highly informative and can help selecting as
robust targets as possible for the drug delivery systems (DDSs)
being developed. However, these technical challenges are not the
only challenges that need to be met, as summarised below (Fig. 2).
Long term goals of most investigations related to drug delivery
systems are associated with their applicability to treat human
diseases (Fig. 2, A). This means that already in the ﬁrst instance it is
important to include human primary tissue samples for the tran-
scriptomic and proteomic analyses. However doing that is related
to several practical questions, such as the availability of mRNA and
cells samples from commercial providers. Even if readily available,
there might be great differences in terms of the age, sex and health/
disease status of donors of the samples, possible contaminationood-brain-barrier transcytosis e perspectives for drug delivery,
.08.025
Fig. 1. Overview of the workﬂow for ﬁnding novel brain microvascular endothelial cell speciﬁc receptors for the delivery of biologicals across the BBB. Primary microvascular
endothelial cells from brain, lung and liver are obtained from a commercial vendor. (A) RNA is extracted from these cells and subjected to transcriptome analysis using next
generation sequencing. (B) Cells are expanded and cell surface proteins are isolated and analysed by LC-MS/MS in parallel. (C) The analysis will reveal which cell surface proteins/
receptors and which transcripts are abundantly and more speciﬁcally expressed in brain microvasculature as compared to the endothelial cells in liver and lung. (D) This helps
identifying novel potential targets that could be exploited for drug delivery across the BBB via transcytosis.
Fig. 2. Challenges of the BBB endothelial transcytosis research. The key goal of (A) developing CNS therapies for human disease dictates the downstream workﬂow. For discovering
novel BBB selective receptors, (B) selection of suitable source cells/RNA must be obtained for (C) the analysis of proteome/transcriptome of selected tissue samples. (D) Target
identiﬁcation and (E) validation are associated with several challenges too, often related to the commercial availability of required materials. Alignment of accessible (F) transcytosis
assays and (G) in vivo models pose both technical challenges and the critical question of translatability of the results to human disease (A). See text for details.
I. M€ager et al. / Neuropharmacology xxx (2016) 1e4 3from other cell types, and the quality of the tissue itself used for
isolation, such as post-explantation (post-mortem) interval etc.
(Fig. 2, B). This, in turn, will obviously increase the variability of the
data set and can considerably decrease the power of the subse-
quent data analysis. Sample variability issues can be partially
controlled by using animal tissues for primary cell isolation instead
of using human primary cell samples provided by contract research
organisation (CROs). However, this can lead investigators too far
from the initial goal of developing a DDS for treating human dis-
eases. In our experience it can be more informative to collect as
detailed information as possible about the used human primary
cell/mRNA samples and to perform principal component analysis
(PCA) on both, the proteomics and NGS data sets (Fig. 2, C) to un-
derstand the factors of sample variance. PCA is a mathematical
technique that can be used to transform complex data set variables
into a set of new independent abstract variables (principal com-
ponents) in order to visualise patterns within the data (Jolliffe,
2002). Because PCA is a powerful tool for describing data set vari-
ability and for ensuring that the gene expression proﬁle of replicate
samples cluster together, it is an important step for estimating the
robustness of the data set.
Once PCA has indicated that enough sample variabilityPlease cite this article in press as: M€ager, I., et al., Targeting bl
Neuropharmacology (2016), http://dx.doi.org/10.1016/j.neuropharm.2016originates from the tissues that the microendothelial cells were
derived from it is possible to move on with target identiﬁcation
(Fig. 2, D). Care must be taken also at this step because both in
proteomic and transcriptomic experiments large numbers of pro-
teins/genes are identiﬁed which can lead to the detection of
number of potentially false positive candidates, even when care-
fully corrected for multiple comparisons. This again is related to
sample variability. In our experience it may be more robust to rely
on false discovery rate (FDR) analysis to identify differentially
expressed proteins/genes rather than strict p-value and fold change
cut-offs.
Once differentially expressed candidate receptors have been
identiﬁed it is essential to validate these targets in various models
(Fig. 2, E). For example, while validation in primary human cell/
mRNA samples can conﬁrm correct target identiﬁcation in the
starting material, it doesn't indicate whether these receptors are
similarly expressed in the used in vitro BBB transcytosis models and
inmodel organisms. Because of their exploratory nature, proteomic
and transcriptomic analyses can lead to the identiﬁcation of pre-
viously poorly studied BBB selective receptor candidates. Receptors
with poorly characterised functions may be highly interesting
target candidates nevertheless. When this occurs, the lack ofood-brain-barrier transcytosis e perspectives for drug delivery,
.08.025
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lenge, potentially requiring generation of custom made antibodies
which can often be a lengthy and costly process. Even when anti-
bodies are available for validating BBB-selective membrane pro-
teins, despite binding the antigen, they still may not be suitable for
functional experiments, e.g. for analysing transcytosis using in vitro
BBB models or for in vivo drug delivery. For example, this can be
related to the epitope recognized by the antibody, its (lack of) cross-
species reactivity, as well as the antibody avidity/afﬁnity which all
may impact functional studies. Experiments with anti-TFRC anti-
bodies revealed that avidity (mono- or bivalent binding) and af-
ﬁnity is important for antibody delivery into the CNS. Even more,
the lack of brain exposure does not disproof a selected receptor as a
suitable target, if strong binding of the tool antibody prevents its
dissociation at the brain side of BBB (Watts and Dennis, 2013; Bien-
Ly et al., 2014; Yu andWatts, 2013). In addition, a “silent” binding of
the DDS to its target receptor may be preferred, since interference
with endogenous ligand binding may block its natural function and
bears a toxicity risk for later therapeutic use (Fig. 2, F).
Next, when moving to in vivo model systems, another layer of
complexity emerges (Fig. 2, G). In addition to above-mentioned
challenges related to choice of species, disease state and trans-
cytosis capacity, it is important to consider the exact target of the
DDS. For example, when drug target is located in the in interstitial
space of the brain, e.g. extracellular amyloid beta deposits, mere
transcytosis of the DDS might be sufﬁcient for observing a thera-
peutic effect. However, for intracellular targeting of neurons or
other brain residing cell types, the transcytosed DDS needs to cross
in addition the plasma membrane of the target cell. An important
question still remains, whether the BBB-targeted DDS with trans-
cytosis capacity is also suitable for subsequent cellular internali-
zation, efﬁcient endosomal escape and the delivery of the
therapeutic payload to the desired cellular compartment. Answer
to those questions must be determined experimentally, e.g. by
analysing whether the transcytosed drug concentration in brain
parenchyma is sufﬁcient for the anticipated biological activity and
whether the observed activity is adequate for therapeutic effect.
Within the COMPACT consortium we are actively tackling
several of the above-described challenges. The multifaceted nature
of the overall aim to discover novel BBB selective receptors with
transcytosis capacity requires careful planning in every step.
Several potential candidate receptors have already been identiﬁed
whereas target validation and applicability testing is currently
ongoing. Despite task complexity we have demonstrated that by
capitalizing on individual expertise of different partners in the
consortium, great progress can be made in the BBB endothelial
transcytosis research.
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